In the clinical trials, a slightly greater number of serious adverse events, discontinuations due to adverse events, and clinically significant ECG changes were reported in patients who received XOPENEX 1.25 mg compared with the other active treatment groups. &4{Q.��㋛zQ������]��K�{_.��f`��?��N����
͏�e�M����rQ�i��X����r^OO��y�x�U���4�y|�HM^�]�����H�G��Op�~�}?�>��o�(w�����l4*⫳��rU�0� ���$����k���k�:�E�u*2�s^s���dY���W��3�xN�D/Q$~����?.>�s����|��]W����i�\��+��\w���-f�
�2�0.�ԡ-�E�.��.�-�,$�����B�d�yZ(�O&��Sd\�ar��j�
0�gCf�� �q x�QY/�}���z^ �C�>;�HV�Z��c��o�Y����.�/���^uK(�Y��z �}x�W���s���ldU���iYM �Jȍ�=3� >wi?w�E�^A �MAǝE�=5����3���>�n���� =��)C�������
2667 0 obj
<>stream
XOPENEX Inhalation Solution has not been approved for the management of preterm labor. Over the 3 week treatment period, there were no significant treatment differences in the Pediatric Asthma Questionnaire (PAQ) total score between groups receiving XOPENEX Inhalation Solution 0.31 mg, XOPENEX Inhalation Solution 0.63 mg, racemic albuterol, and placebo. XOPENEX Inhalation Solution, like other beta-adrenergic agonists, can produce clinically significant cardiovascular effects in some patients, as measured by heart rate, blood pressure, and symptoms.
Inhalation Solution For Oral Inhalation Only. Each XOPENEX HFA 15 gram canister contains 200 metered actuations (or inhalations).
Inhalation Solution For Oral Inhalation Only. Do not exceed recommended dose. Therefore, patients with asthma should not normally be treated with beta-blockers. hބ�Qk�0��J�QnRۨ ��N-L'V�@|�mViSڌ��~I��q/!��sr�G(A����X@�z�R���>~y^?E���:��5��K�,�GXfi>���Y���+y'�j����Bc8�J��Fq��|�g�J^�(� G���-k��� �1�)�N�Zu�Fq�C˭�N��{:��$���`~�D�)���m6'�d톋�
)�h�x>�����uI���^ΐ7�S�8ا��X-�0rH�a���]����zڇ��?�X�;���TW3�N��S�!�L�"n*����~CdB;? (Most common adverse reactions are: palpitations, chest pain, tachycardia, headache, dizziness, tremor and nervousness. Morgantown, WV: Mylan Pharmaceuticals, Inc.;2009 March. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. general, patients 65 years of age and older should be started at lower doses (e.g., a dose of 0.63 mgper nebulizer dose). XOPENEX Inhalation Solution is not a substitute for corticosteroids. Inform patients using XOPENEX Inhalation Solution, that other inhaled drugs and asthma medications should be taken only as directed by their physician. Large doses of intravenous racemic albuterol have been reported to aggravate preexisting diabetes mellitus and ketoacidosis.
The exact cause of death is unknown, but cardiac arrest following an unexpected development of a severe acute asthmatic crisis and subsequent hypoxia is suspected.
100 . There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to asthma medication, including XOPENEX, during pregnancy.
Changes in blood glucose may occur. If the patient needs more doses of XOPENEX Inhalation Solution than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. arrhythmias; in patients with convulsive disorders, hyperthyroidism, or diabetes mellitus; and in . All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent. Therefore, XOPENEX Inhalation Solution, like all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension. XOPENEX Inhalation Solution is supplied in 3 mL unit-dose, low-density polyethylene (LDPE) vials as a clear, colorless, sterile, preservative-free, aqueous solution, in three different strengths of levalbuterol (0.31 mg, 0.63 mg, 1.25 mg). Note: Subjects may have more than one adverse event per body system and preferred term. 101 . Table 4: Mean Changes from Baseline Heart Rate at 30 Minutes and Glucose and Potassium at 1 Hour after First Dose (Day 1) and Last Dose (Day 21) in Children 6-11 Years Old You can ask your pharmacist or doctor for information about XOPENEX Inhalation Solution that is written for health professionals. 17478-174-12, Read this Patient Information before you start to use XOPENEX Inhalation Solution and each time you get a refill. XOPENEX Inhalation Solution, like all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, hypertension, and cardiac arrhythmias; in patients with convulsive disorders, hyperthyroidism, or diabetes mellitus; and in patients who are unusually responsive to sympathomimetic amines. Changes in heart rate, plasma glucose, and serum potassium are shown in